Core Viewpoint - The performance of the new consumption sector shows significant divergence, with companies like Pop Mart achieving impressive growth, while the capital market does not seem to respond positively, leading to a stark contrast between "performance growth and valuation adjustment" [1] Group 1: IP Economy Performance - Pop Mart's Q3 2025 financial report shows a substantial revenue increase of 245%-250% year-on-year, continuing its high growth trend from the first half of the year [3] - In the Chinese market, Q3 revenue grew by 185%-190%, with online channels surging by 300%-305% and offline channels increasing by 130%-135% [3] - The overseas market saw even more remarkable growth, with overall revenue up by 365%-370%, and the Americas market skyrocketing by 1265%-1270% [3] - Light Media, a leading company in the IP economy, reported a 150.81% increase in revenue to 3.616 billion yuan and a 406.78% rise in net profit to 2.336 billion yuan for the first three quarters [4] - Despite these impressive results, companies like Pop Mart and Light Media experienced notable stock price adjustments, indicating that the market is more focused on sustainable growth potential and the ability to localize operations in overseas markets [4] Group 2: Pet Economy Growth - The pet economy has been a favored sector in the capital market, with companies like Zhongchong Co. and Guai Bao Pet seeing stock price increases until recently, when performance growth began to slow [6] - Zhongchong Co. reported a revenue of 3.860 billion yuan for the first three quarters, a year-on-year increase of 21.05%, and a net profit of 333 million yuan, up 18.21% [7] - Guai Bao Pet achieved a revenue of 4.737 billion yuan, a 29.03% increase, and a net profit of 513 million yuan, up 9.05% [8] - The pet market in China is still in its early stages compared to developed countries, with significant opportunities for growth as consumer demand diversifies [8][9] Group 3: Beauty Economy Decline - Companies in the beauty economy, such as Aimeike, Huaxi Biological, and Beitaini, are facing dual challenges of declining performance and valuation adjustments [10] - Aimeike's Q3 report shows a revenue of 1.865 billion yuan, down 21.49%, and a net profit of 1.093 billion yuan, down 31.05% [12] - Huaxi Biological reported a total revenue of 3.163 billion yuan, a decrease of 18.36%, and a net profit of 252 million yuan, down 30.29% [13] - Beitaini's revenue for the first three quarters was 3.464 billion yuan, down 13.78%, with a net profit of 272 million yuan, down 34.45% [14] - The medical beauty industry is experiencing a strategic transformation, with a focus on high-end markets and product innovation, which may provide growth opportunities in the future [15]